Departmental Upgrade, United for a New Journey-KUNMING TONGREN HOSPITAL

Home page

Departmental Upgrade, United for a New Journey

2026-06-29

On May 9, the Department of Nuclear Medicine of Kunming Tongren Hospital officially opened its doors. Duan Zhicong, President of Kunming Tongren Hospital, Tang Bin, Vice President, directors of all clinical departments and heads of functional departments gathered at the scene to witness this milestone moment together.

At the opening ceremony, President Duan Zhicong, on behalf of the hospital group’s leadership, extended warm congratulations on the official launch of the Department of Nuclear Medicine and sincere gratitude to all staff who dedicated themselves to the department’s preparation. He stated that as a high-end technical platform integrating advanced imaging examinations and radionuclide therapy, the Department of Nuclear Medicine shall forge close collaboration with all clinical departments and fully leverage its technological strengths. This enables patients from Yunnan and surrounding regions to access state-of-the-art, high-standard nuclear medicine diagnosis and treatment services locally. The inauguration marks a major leap forward in the hospital’s overall medical capacity and signals the official launch of the Phase II Tumor Diagnosis and Treatment Center of Kunming Tongren Hospital, offering patients more precise and convenient treatment options.

(President Duan Zhicong, Kunming Tongren Hospital)

Multiple Self-Developed Imaging Technologies for Multisystem Disease Screening

Boasting a team with years of expertise in nuclear medicine, the Department of Nuclear Medicine is equipped with cutting-edge imaging systems, including PET/CT and SPECT/CT, and integrates a range of self-developed innovative imaging technologies, with a strong focus on the diagnosis of complex tumors.

Powered by high-sensitivity metabolic imaging, the department accurately detects occult and small lesions throughout the body, differentiates benign from malignant tumors, and identifies both primary and metastatic lesions. It overcomes many of the limitations of conventional imaging, such as missed diagnoses, inconclusive lesion characterization, and inaccurate staging.

The department provides full-cycle, integrated precision imaging support for tumor patients, covering preoperative staging, treatment planning, postoperative recurrence monitoring, and the evaluation of radiotherapy and chemotherapy outcomes.

For neurological disorders, the department pioneered the multimodal PET/CT/MR NeuroFusion 3D Neural Fusion Technology, which integrates the core strengths of PET metabolic imaging, CT anatomical localization, and high-resolution MR soft-tissue imaging to overcome the limitations of single-modality imaging.

This technology enables three-dimensional integrated reconstruction of brain tissue structure, cellular metabolism, and neural function, allowing highly precise detection of micro and occult brain lesions. It addresses longstanding challenges associated with conventional imaging, including difficulties in distinguishing benign from malignant lesions and accurately defining lesion boundaries, thereby supporting the early detection and accurate diagnosis of brain tumors, cerebrovascular diseases, neurodegenerative disorders, central nervous system inflammation, and other neurological conditions.

For cardiovascular diseases, the department independently developed dual-glucose-mode myocardial metabolic imaging technology, which detects myocardial cell viability and quantifies myocardial metabolic levels and blood supply function, clearly distinguishing reversible myocardial injury from irreversible myocardial necrosis. In addition, the department advances diagnosis of digestive and parenchymal organ disorders, regularly conducting specialized examinations such as thyroid, liver and splenic parenchymal organ volumetry, hepatic and renal metabolic functional imaging, and gastrointestinal motility imaging for screening and diagnosis of organ function-related illnesses.

3D Stereoscopic Imaging Technology Enables Intuitive Lesion Visualization

To address the limitations of conventional 2D imaging—including flat planar displays, unclear spatial relationships between lesions and surrounding structures, and the challenges they pose for clinical diagnosis—the department has innovatively introduced PET/CT 3D stereoscopic visualization technology, supporting both stereoscopic and glasses-free 3D viewing, to comprehensively enhance diagnostic imaging.

Traditional 2D imaging provides only planar views of lesions and cannot intuitively demonstrate their depth, volume, or anatomical relationships with blood vessels, nerves, and surrounding organs. In contrast, the department’s proprietary dual-mode 3D imaging technology reconstructs the complete three-dimensional structure of lesions, clearly displaying their size, morphology, extent of infiltration, and spatial relationships with adjacent healthy tissues.

This technology reduces diagnostic errors in complex lesions and provides intuitive, accurate visual guidance for minimally invasive surgical planning, precise tumor ablation, radiotherapy target delineation, and postoperative efficacy assessment, ultimately enhancing the precision of diagnosis and treatment for intractable diseases.

Kunming Tongren Hospital Officially Opens Its Traditional Chinese Medicine Inpatient Ward

News & Media